Multivariate regression analysis indicated that status of miR-127 expression (relative risk (RR), 1.798; 95% confidence interval (CI), 1.333–2.552; P = 0.038) was significantly correlated with OS of BC patients, along with HER-2 status (P = 0.028), lymph node metastasis (P = 0.007), and clinical stage (P = 0.025). This evidence concerns the gene ERBB2 and breast cancer.